Journal of Experimental & Clinical Cancer Research

USP43 promotes gemcitabine resistance in bladder cancer by stabilizing E2F1 to regulate cholesterol homeostasis

Gemcitabine (GEM) resistance remains a critical barrier in the treatment of bladder cancer (BLCA). Based on the observation that metabolic reprogramming drives chemoresistance, we identified USP43 as a promoter of GEM resistance via an E2F1-driven mechanism that modulates cholesterol metabolism.

Lingao Ju and 4 others

Jan 07, 2026

Behind the Paper

YKT6 drives bladder cancer progression by stabilizing β-catenin via a USP7-mediated mechanism

Bladder cancer (BLCA) remains a highly lethal malignancy with limited therapeutic strategies. In our latest study, we investigated the oncogenic role of YKT6, a conserved SNARE protein, in BLCA progression.

Yu Xiao and 4 others

Jan 06, 2026

Behind the Paper

FBXW7/GSK3β-mediated proline-rich 11 degradation promotes oxidative DNA damage and inhibits tumor progression in renal cell carcinoma

RCC exhibits defects in homologous recombination and oxidative DNA damage. Our study shows that PRR11, upregulated in RCC, promotes proliferation and migration via AKT signaling. This activation inhibits GSK3β/FBXW7-mediated PRR11 degradation, forming a feedback loop that worsens RCC progression.

Lingao Ju and 4 others

Feb 05, 2025

Behind the Paper

DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization

Our study shows that DLGAP5 enhances gemcitabine resistance in bladder cancer by stabilizing MYC protein via USP11-mediated deubiquitination. This interaction boosts MYC-driven glycolysis, suggesting that targeting the DLGAP5-USP11-MYC axis could overcome resistance.

Yu Xiao and 4 others

Jan 20, 2025

Behind the Paper

Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis

CUT&Tag sequencing reveals how the androgen receptor (AR) drives tumor heterogeneity and gender disparities in bladder cancer through epigenetic reprogramming.

Yu Xiao and 3 others

Dec 28, 2024

Cell Death Discovery

Behind the Paper

Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways

Pectolinarigenin (PEC) from herbal medicine targets DNA topoisomerase II alpha (TOP2A) in bladder cancer (BLCA), causing DNA damage and blocking cell division. It inhibits autophagy, boosting its effectiveness. Combined with gemcitabine, PEC more effectively halts BLCA growth.

Yu Xiao and 4 others

Oct 20, 2024

Cell Death & Disease

Behind the Paper

Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis

Melatonin may help fight bladder cancer (BLCA) by slowing cancer cell energy production and increasing chemotherapy effectiveness, by targeting ENO1 to enhance gemcitabine’s impact and involving reactive oxygen species and PPARγ regulation. This suggests new methods for improving BLCA treatment.

Yu Xiao and 4 others

Oct 20, 2024

Oncogene

Behind the Paper

MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3

Our research reveals that MYBL2, a gene-regulating protein, is elevated in bladder cancer (BLCA) and linked to worse patient outcomes. It boosts BLCA growth and spread by activating the CDCA3 gene, working with FOXM1 to enhance cancer traits. This identifies MYBL2 as a key promoter of BLCA.

Yu Xiao and 3 others

Oct 18, 2024

Behind the Paper

Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNAmethylation in a prospective cohort study

We studied DNA methylation markers in urine to enhance bladder cancer detection and classification. Our findings could transform non-invasive diagnosis and monitoring of this cancer and potentially other types as well, leading to major advances in cancer management with less invasive techniques.

Yu Xiao and 3 others

Oct 17, 2024

Behind the Paper

Integrative single cell atlas revealed intratumoral heterogeneity generation from an adaptive epigenetic cell state in human bladder urothelial carcinoma

A subgroup of bladder cancer cells marked by TM4SF1 expression is a key source of tumor diversity (ITH). These cells, which show stem-cell features and foster various cell types within the tumor, are linked to more advanced cancer stages and poorer outcomes.

Yu Xiao and 3 others

Oct 16, 2024

Oncogene

Behind the Paper

A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype

This study is the first report identifying a pathogenic EGFR germline mutation in prostate cancer, suggesting venues for germline screening, non-invasive diagnosis and monitoring in clinical practice.

Yu Xiao and 3 others

Oct 16, 2024

Biomarker Research

Behind the Paper

The detection, biological function, and liquid biopsy application of extracellular vesicle-associated DNA

This review summarizes and discusses advances in EV-associated DNA (EV-DNA) research, with an emphasis on EV-DNA detection at the population-EV and single-EV levels, gene transfer-associated biological functions, and clinical applications as biomarkers for disease liquid biopsy.

Kaiyu Qian and 4 others

Oct 16, 2024

Behind the Paper

Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT

We identified USP52 as a DUB that cleaves K48-linked ubiquitin at K4 and K12 of xCT. Loss of USP52 reduces cell proliferation by decreasing xCT and enhancing ferroptosis sensitivity. Combining USP52 depletion with IKE strongly inhibits BLCA progression, presenting a new potential therapy.

Kaiyu Qian and 4 others

Oct 11, 2024

Nature Communications

Behind the Paper

DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC

Based on the bladder cancer (BLCA) pedigree containing germline mutation of POLD1 found in our last study, we further analyzed the molecular role of POLD1 driving tumorigenesis. We identified POLD1 as a promotor of BLCA via a MYC driven mechanism.

Yu Xiao and 3 others

Oct 11, 2024

Cellular & Molecular Immunology

Behind the Paper

Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival

We found a bladder cancer family in which germline mutations of POLD1 and somatic mutations of FGFR3 were prevalent. We studied the changes in the immune microenvironment in patients with this mutation in our cohort and a TCGA cohort and predicted the prognosis of patients with this subtype.

Yu Xiao and 3 others

Oct 10, 2024

The Pharmacogenomics Journal

Behind the Paper

Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: A comprehensive analysis using Mendelian randomization, animal models, and transcriptomics

Our study identifies HMG-CoA reductase (HMGCR) inhibitors, particularly simvastatin, as potential agents for reducing bladder cancer (BLCA) risk, and provides potential insight for clinical practice for BLCA treatment or adjuvant therapy.

Yu Xiao and 3 others

Aug 11, 2024

Parkin inhibits proliferation and migration of bladder cancer via ubiquitinating Catalase

Communications Biology

Behind the Paper

Parkin inhibits proliferation and migration of bladder cancer via ubiquitinating Catalase

Lingao Ju and 4 others

Mar 01, 2024

Cell Death & Disease

Behind the Paper

USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer

This study identified USP43 as a deubiquitinase which regulates glycolytic metabolism and c-Myc transcriptional activity and revealed a USP43/c-Myc positive feedback loop that contributes to the progression of BLCA.

Yu Xiao and 2 others

Jan 14, 2024

Oncogene

Behind the Paper

TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC

This study identified the significant role of TRAIP in inhibiting BLCA progression, and revealed that TRAIP expression is significantly downregulated in BLCA and is strongly associated with poor prognosis.

Yu Xiao and 2 others

Dec 21, 2023

Cookies

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.

Further information can be found in our privacy policy.

Yi Zhang

Cookies